ImmunityBio (IBRX) opened Q1 2026 with revenue of US$44.2 million and a basic EPS loss of US$0.62, alongside a net income loss of US$632.8 million, putting a sharp spotlight on how much cash the business is burning to drive its pipeline. The company has seen quarterly revenue move from US$7.6 million in Q4 2024 to US$16.5 million in Q1 2025, US$38.3 million in Q4 2025 and now US$44.2 million in Q1 2026, while quarterly basic EPS has stayed in loss territory over the same stretch. The key question for investors is how quickly that top line can scale relative to the current level of losses and margin pressure.

See our full analysis for ImmunityBio.

With the headline numbers on the table, the next step is to see how this mix of growing revenue and deep losses lines up with the dominant narratives investors follow around ImmunityBio's growth potential and risk profile.

Revenue climbs to US$141 million over the past year

• On a trailing 12 month basis, ImmunityBio booked US$140.98 million in revenue, compared with US$31.22 million a year earlier on the same trailing basis, highlighting how much of the story now depends on ANKTIVA sales holding up.
• Bulls point to this higher revenue base alongside forecasts of about 54.5% annual revenue growth and earnings growth of roughly 68.7% per year as evidence that the current loss profile could eventually be absorbed by scale.
  • That optimistic view leans heavily on revenue potentially rising far faster than the 11.4% figure used for the broader US market comparator in the dataset.
  • At the same time, the company reported a trailing 12 month net loss of US$854.53 million and basic EPS of US$0.89 in losses, which means the bullish case assumes a sizeable shift in profitability from where the numbers sit today.

Investors who think that rapid revenue expansion can carry this loss profile often want to see how the full bullish thesis fits together over time, not just this quarter’s snapshot. It can help to step back and read the bigger picture in context before deciding how much growth risk feels acceptable. 🐂 ImmunityBio Bull Case

Q1 loss of US$632.8 million stresses the balance sheet story

• For Q1 2026, ImmunityBio recorded a net loss of US$632.78 million on US$44.21 million of revenue, while trailing 12 month net losses reached US$854.53 million alongside negative shareholders’ equity and a P/B of 9.2x in the data.
• Bears argue that this combination of deep losses, negative equity and a negative P/B ratio is hard to ignore, even with strong growth forecasts in the background.
  • The risk summary explicitly highlights negative shareholders’ equity, trailing 12 month unprofitability and high share price volatility over the last three months as key concerns.
  • Shareholder dilution over the past year is also flagged, which means any future capital raising to fund these losses could spread those earnings forecasts over an even larger share count.

Skeptics who focus on balance sheet strength and earnings quality often want to see how these risks are laid out side by side with the cautious case on growth and approvals before deciding how much downside they are comfortable taking on. 🐻 ImmunityBio Bear Case

DCF fair value of US$36.33 contrasts with US$7.76 price

• The analysis dataset points to a DCF fair value of US$36.33 per share, while the current share price is US$7.76 and the only allowed analyst price target here is US$15.75, so the stock is trading well below both those reference points.
• Consensus style commentary highlights that forecasts for rapid revenue and earnings growth sit beside this valuation gap, which can cut both ways for investors weighing upside against execution risk.
  • The DCF input suggests the stock is trading roughly 78.6% below that model’s fair value estimate, which is a wide spread for a company that is still loss making on US$854.53 million of trailing net losses.
  • Analysts in the provided data also expect margins to move from roughly 310.2% in losses today to positive territory over a few years, so anyone relying on these targets is really betting that the shift in profitability materializes from the current baseline.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for ImmunityBio on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seeing both strong growth forecasts and heavy losses in the same story can feel mixed, so move quickly, review the data, and weigh the 2 key rewards and 3 important warning signs

See What Else Is Out There

ImmunityBio is carrying very heavy losses, negative shareholders’ equity and balance sheet stress, which raises clear questions about resilience if conditions get tougher.

If that level of risk feels uncomfortable, compare it with companies screened for stronger finances by checking the solid balance sheet and fundamentals stocks screener (44 results) today while the opportunity set is still fresh.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.